In the clinic, HDAC inhibition with SAHA (Vorinistat) has been combined with carboplatin and gemcitabine in a phase I trial that demonstrated partial responses in 6 out 7 women with recurrent ovarian cancer, though the trial was stopped early due to excessive toxicity [32]. This evidence concerns the gene HDAC9 and ovarian cancer.